Deepmatter Share Discussion Threads

[1347] 22/9/2021 10:04

What's more important is that few seem interested in paying much for their platform. No wonder Griff is heading for the door. Need some decent contracts soon, not pie in the sky collaborations.

[yump] 22/9/2021 09:47

So basically nobody here is actually interested in the business.

[deutsch4] 22/9/2021 09:30

Another DHSS dependant on the taxpayer.

[yump] 22/9/2021 09:17

So do you have some idea of how long increasing sales are likely to take with a business like this ?

Or how long the sales process is likely to be ?

I don’t think anyone has - there’s nothing to compare with.

Can only take a view on the business model and have it as part of a speculative portfolio.

[1347] 22/9/2021 09:12

Maybe they should register as a charity? share price tanked, IMC at 9:30 will be a waste of time, what exactly have they achieved this year?

[thiopia] 22/9/2021 08:57

'Freemium' model

They can't sell it.

The only revenue they have they bought in from that Springer acquisition.

Even that Revenue collapsed half on half.

DOWN from c. 0.8m to 0.6m

[1347] 22/9/2021 08:38

Dispappointed, for all their vaunted contacts with Pharmas and Universities they simply aren't going anywhere revenue or earnings wise, are they giving it away? Will they ever reach an inflection point or just bump along making enough to cover Director's costs? In danger of becoming just another AIM lifestyle company.

[pugugly] 22/9/2021 08:10

This is a reminder that DEEPMATTER GROUP PLC will shortly be holding the meeting Half year results at 9:30am.

From Investor meet Company.

[yump] 22/9/2021 08:05

PS
The big opportunity here is the likely gearing that will kick in on relatively small revenues.

They’re running at 1.5mln ish.

Pencil in £2.5mln and everything will look totally different. Difficult to know how far off that is yet.

[yump] 22/9/2021 07:59

Cash left is about where I thought it would be, so at the burn rate they’ll have about 1mln at year end.

A bit vague on outlook and this half is up on the comparative half but down a bit on H2 last year. How much of that is due to difficulty signing up new customers during Jan to June because of covid, isn’t clear.

The second half is quite critical imo - they could do with some more traction just to show tangible increasing demand.

Early days for something like this of course.

In theory, increased data = more value and increased clients = more data. Which could be a formula for exponential revenue growth but who knows when !

Revenues are tiny at the moment and its not yet clear what potential there is. Last year there was a jump from 0.54 to 0.76 mln.

The general trend is up - thats all there is at the moment.

[the stigologist] 22/9/2021 07:40

"The cash balance at the 30 June 2020 was £1.8m. Based on scenarios modelled, the Directors have a reasonable expectation that the Group has adequate resources to be a going concern in addition to which, the Directors may choose to fundraise or engage in other strategic arrangements."

[thiopia] 21/9/2021 21:13

Chart breakdown to 1p looking likely

[yump] 21/9/2021 10:10

Might be another fundraise coming - they had 2.6mln Dec 2020, reckon they're burning about 1.5mln a year, so they'll want to have more than 1mln left by Dec 2021. Perhaps about 1.8mln left at half year June 2021. Unless they've hauled in some more revenue.

I make it 0.54mln first half and 0.76 second half last year, so be interesting to see if that has increased first half this year.

Might explain the gradual dropping price.

Since year end there's been the three year contract with Thieme and licence with Merck - unknown values. Other announcements were collaborations.

Depends a lot on what proportion of previous revenues are recurring.

[janhar] 21/9/2021 09:25

Results tomorrow ??

[wololol] 01/9/2021 13:37

Is RG out?

[wololol] 31/8/2021 17:16

What's with the 9million trade?

[yump] 31/8/2021 11:56

Some of the stuff that's going on is very cool.

Very o/t - reminds me of DNA data storage:

[supernumerary] 27/8/2021 16:54

Not directly relevant, but interesting as a sign of where synthetic biology is heading, and remember viruses are only chunks of chemicals:



Humane Genomics is 3D-printing oncolytic viruses to treat rare cancers
by Amirah Al Idrus | Aug 27, 2021 10:45am

Oncolytic viruses have long held promise for cancer treatment, but their first generation hasn’t quite delivered. Armed with new tools and technology—including 3D printing—Humane Genomics is part of a wave of companies working on oncolytic viruses 2.0.

The only FDA-approved oncolytic virus is Amgen’s Imlygic, which scored a nod in 2015 for the treatment of melanoma. Based on a herpes virus, the treatment is injected into tumors, where it replicates and produces GM-CSF, a protein that stimulates the immune response.

However, Imlygic doesn’t work in metastatic disease, and cancer-killing viruses as a whole face other barriers. A major hurdle is delivery: The viruses must be injected directly into tumors, because the immune system may catch and destroy them before they reach cancer cells if they are given intravenously. Another challenge is efficacy. The treatments don’t seem to work well on their own, and multiple companies are pursuing combinations, such as with checkpoint inhibitors and other immunotherapies.

New York-based Humane Genomics is building a platform that can design cancer-killing viruses from scratch as well as produce them and test them more quickly and cheaply than other methods.

“We can 3D print or synthesize DNA based on a computer file,” said Humane Genomics CEO Peter Weijmarshausen. “We take a file that contains A, G, C and T in the right order and feed it into a machine that produces DNA fragments,” he added, referring to the nucleotide bases or letters that are the building blocks of DNA.

Humane Genomics aims to develop viruses that not only target cancer cells while sparing healthy ones but that can also carry drugs to boost the virus’s effects or dial up the immune response against the tumor.

Weijmarshausen founded Humane Genomics with Andrew Hessel and Chad Moles, the company’s chief science officer, who focused on synthetic virology during his graduate study in biotechnology. The company picked up $125,000 in seed funding from Y Combinator this year and stands to raise more after pitching its work to investors at the startup accelerator’s Demo Day next week.

“It turns out to make a virus that is really good at identifying cancer cells and killing them requires quite a bit of engineering,” Weijmarshausen said. “It’s not that we didn’t know how to do it, but until quite recently, science lacked the tools to do it well.”

Synthetic biology, the science of redesigning organisms such as viruses for useful purposes, is just one part of the equation. The rising availability and decreasing costs of genome sequencing is the other.

Sequencing has helped drug developers understand how cancer cells are different from healthy cells and led to the creation of drugs that zero in on cancer-driving genes.

“The same is true for viruses,” Weijmarshausen said. With sequencing, scientists have learned how viruses found in nature work and can use that understanding to build synthetic viruses to fight cancer.

"We can make a new virus in about a week, and it costs a few hundred dollars,” Weijmarshausen said. In contrast, using CRISPR-based gene editing to modify a naturally occurring virus could take many more weeks and thousands of dollars, he added.

“As a result, we can take some wild gambles … This platform is completely synthetic. We are not making edits, but writing viruses from scratch, which allows us to test concepts that are going to be difficult otherwise,” Weijmarshausen said.

Instead of modifying natural viruses like herpes virus or vesicular stomatitis virus to fight cancer—and putting up with potential trade-offs or side effects—Human Genomics is cherry-picking the most desirable qualities found in natural viruses and using them to build synthetic viruses.

The company is developing its first programs for the treatment of bone cancer, liver cancer, small-cell lung cancer and a form of brain cancer called glioblastoma. It’s starting with these cancers because they’re on the rarer side and they don’t have great treatments, Weijmarshausen said.

In the near term, Humane Genomics will work on experiments to show its viruses work in mice. It is also on the hunt for partners among institutions that treat patients with the cancer types it’s interested in.

Further down the line, Weijmarshausen sees synthetic oncolytic viruses as personalized treatments to be deployed alongside routine blood testing for the earliest signs of cancer.

“Based on that detection in the blood, we’ll already know how to engineer a virus that can take care of that kind of cancer. We make it, or have it on the shelf, and you get a shot,” he said. “You may have a bit of a flu for a few days, but without you noticing you had one form of cancer or another, the virus will have killed it."

[ragnarr] 27/8/2021 12:48

An interesting read for any investors hereDigital Chemistry: A new era for digital molecular design and fabricationhttps://www.imperial.ac.uk/media/imperial-college/research-centres-and-groups/digifab/IBP-Tech-Digest---Digital-Chemistry.pdf

[gspanner] 25/8/2021 16:41

Totally agree yump. Seems to be innovative tech, covid aside will be increasingly used and become better with time, management not the usual AIM director remuneration conveyerbelt. Buy a chunk, hold forever... Or until the above changes!

[ragnarr] 25/8/2021 11:58

Err - is that blue i see

[yump] 05/8/2021 17:34

I’ve had a few of these for a while now as part of a speculative “if they did...” portfolio based on possible ground-breaking tech/products at an early stage.

Still difficult to assess the real potential but quite a few steps in the right direction - not just one-offs.

Plus it appears to be run by a genuinely interested group - not financial “operatorsR21;.

From what I’ve read automated reaction replication is going to be a big growth area but don’t ask me when it will hit mainsteam investor interest !

[ragnarr] 05/8/2021 13:18

https://www.idmt.online/grandopening

[ragnarr] 05/8/2021 13:15

DeepMatter Group PLC - Bristol-based company focused on digitising chemistry - Teams with University of Cambridge's Innovation Centre in Digital Molecular Technologies arm. IDMT is co-funded by the university, as well as AstraZeneca PLC, Shionogi, and the European Regional Development Fund. DeepMatter to provide its DigitalGlassware cloud-based digital chemistry platform. "DeepMatter will provide its DigitalGlassware platform to iDMT as part of the development of a fully digital workflow in the discovery and development of new molecules, materials, reactions and processes," company explains.

[ragnarr] 05/8/2021 11:22

Why do you bother posting if you are not interested